St. Jude Care & Treatment

Menu

Close

Recruiting

3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors

About this study

This study looks at a new treatment for children and young adults with solid tumors that have been difficult to treat (refractory) or have come back after treatment (relapsed).

The new treatment is called CAR T-cell therapy. CAR T-cell therapy is a type of immunotherapy. It uses infection-fighting cells from the body’s immune system to target cancer cells. The infection-fighting cells used in this study are called T cells. Scientists insert a protein called a chimeric antigen receptor (CAR) into T cells to give them the ability to kill cancer cells. The CAR T-cell target in this study is a particle called B7-H3. B7-H3 is found on many different types of pediatric solid tumors.

Eligibility overview

Inclusion criteria

  • Up to 21 years old
  • Relapsed or refractory B7-H3-positive solid tumor
  • Measurable disease (evaluable disease for patients with neuroblastoma)
  • Adequate heart, lung, liver, kidney and bone marrow function

Exclusion criteria

  • History of HIV infection
  • Therapy that will interfere with B7-H3-CAR T-cell function within 14 days prior to CAR T cell infusion
  • Rapidly progressing disease
  • Known underlying medical condition for which participation would not be in the best interest of the participant or that could prevent, limit or confound protocol assessments

Request a referral

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

3CAR: B7-H3-specific Chimeric Antigen Receptor Autologous T-cell Therapy for Pediatric Patients with Solid Tumors

Study goal:

The main purpose of 3CAR is to find out if this type of immunotherapy is safe for pediatric patients with solid tumors. We also want to learn if it is effective in fighting solid tumors.

Diagnosis:

Solid Tumor

Age:

Up to 21 years old

Clinical trials categories:

Ewing Sarcoma Childhood Cancer Desmoplastic Small Round Cell Tumor Hepatoblastoma Germ Cell Tumors (Solid Tumor) Solid Tumors Adrenocortical Tumor Rhabdomyosarcoma Melanoma Carcinoma Osteosarcoma Wilms Tumor Neuroblastoma

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more